Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
The week’s five health sector IPOs have produced lackluster returns; together they are down 1% on average from their IPO prices. Amedica (AMDA), which creates improved spine, hip and joint replacements, dropped 6% today after pricing at the largest...read more
Eagle Pharmaceuticals, which develops and sells enhanced injectable versions of expiring patented drugs, raised $50 million by offering 3.4 million shares at $15, the midpoint of the range of $14 to $16. Eagle Pharmaceuticals plans to list on the NASDAQ under...read more
US IPO Recap: Wave goodbye to the biotech wave as tech prepares to take over
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
Health IPOs down 1% and housing IPOs trade up after heavy discount
The week’s five health sector IPOs have produced lackluster returns; together they are down 1% on average from their IPO prices. Amedica (AMDA), which creates improved spine, hip and joint replacements, dropped 6% today after pricing at the largest...read more
Eagle Pharmaceuticals prices IPO at $15, the midpoint of the range
Eagle Pharmaceuticals, which develops and sells enhanced injectable versions of expiring patented drugs, raised $50 million by offering 3.4 million shares at $15, the midpoint of the range of $14 to $16. Eagle Pharmaceuticals plans to list on the NASDAQ under...read more
9 US IPOs planned for the week of Feb 10
The following IPOs are expected to price this week: Amedica (AMDA), which develops and sells medical devices using its silicon nitride technology platform, plans to...read more